Abstract
We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.
| Original language | English |
|---|---|
| Pages (from-to) | e27-e30 |
| Journal | Diabetes Research and Clinical Practice |
| Volume | 110 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2015 Dec 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
}
Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks : An open-label extension study. / Kim, Sun Hwa; Kim, Sin Gon; Kim, Doo Man; Woo, Jeong Taek; Jang, Hak Chul; Chung, Choon Hee; Ko, Kyung Soo; Park, Jeong Hyun; Park, Yong Soo; Kim, Sang Jin; Choi, Dong Seop.
In: Diabetes Research and Clinical Practice, Vol. 110, No. 3, 01.12.2015, p. e27-e30.Research output: Contribution to journal › Article
TY - JOUR
T1 - Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks
T2 - An open-label extension study
AU - Kim, Sun Hwa
AU - Kim, Sin Gon
AU - Kim, Doo Man
AU - Woo, Jeong Taek
AU - Jang, Hak Chul
AU - Chung, Choon Hee
AU - Ko, Kyung Soo
AU - Park, Jeong Hyun
AU - Park, Yong Soo
AU - Kim, Sang Jin
AU - Choi, Dong Seop
PY - 2015/12/1
Y1 - 2015/12/1
N2 - We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.
AB - We aimed to assess the safety and efficacy of lobeglitazone in patients with type 2 diabetes over 52 weeks through 28-week extension study. Clinical benefits in terms of glycemic and lipid control were maintained for 52 weeks. Lobeglitazone showed a favorable balance of efficacy and safety during the extension study.
UR - http://www.scopus.com/inward/record.url?scp=84955202578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84955202578&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2015.09.009
DO - 10.1016/j.diabres.2015.09.009
M3 - Article
C2 - 26458774
AN - SCOPUS:84955202578
VL - 110
SP - e27-e30
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
IS - 3
ER -